Edgestream Partners’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $225K | Buy |
+1,181
| New | +$203K | 0.01% | 904 |
|
|
2026
Q1 | – | Sell |
-2,233
| Closed | -$377K | – | 974 |
|
|
2025
Q4 | $377K | Buy |
+2,233
| New | +$363K | 0.01% | 853 |
|
|
2025
Q3 | – | Sell |
-1,837
| Closed | -$232K | – | 966 |
|
|
2025
Q2 | $232K | Buy |
+1,837
| New | +$226K | 0.01% | 810 |
|
|
2024
Q4 | – | Sell |
-2,272
| Closed | -$331K | – | 956 |
|
|
2024
Q3 | $331K | Sell |
2,272
-1,500
| -40% | -$217K | 0.01% | 758 |
|
|
2024
Q2 | $518K | Buy |
3,772
+591
| +19% | +$78.9K | 0.02% | 664 |
|
|
2024
Q1 | $436K | Buy |
+3,181
| New | +$434K | 0.02% | 670 |
|
|
2023
Q4 | – | Sell |
-9,386
| Closed | -$1.15M | – | 940 |
|
|
2023
Q3 | $1.15M | Buy |
9,386
+5,578
| +146% | +$709K | 0.09% | 356 |
|
|
2023
Q2 | $483K | Buy |
3,808
+410
| +12% | +$53.3K | 0.04% | 533 |
|
|
2023
Q1 | $439K | Buy |
+3,398
| New | +$445K | 0.05% | 418 |
|
|
2022
Q4 | – | Sell |
-4,071
| Closed | -$476K | – | 558 |
|
|
2022
Q3 | $476K | Buy |
+4,071
| New | +$506K | 0.04% | 345 |
|
|
2022
Q2 | – | Sell |
-2,897
| Closed | -$377K | – | 559 |
|
|
2022
Q1 | $377K | Buy |
2,897
+1,400
| +94% | +$182K | 0.03% | 460 |
|
|
2021
Q4 | $228K | Sell |
1,497
-2,608
| -64% | -$404K | 0.01% | 458 |
|
|
2021
Q3 | $664K | Buy |
4,105
+1,952
| +91% | +$328K | 0.04% | 364 |
|
|
2021
Q2 | $352K | Buy |
+2,153
| New | +$332K | 0.02% | 377 |
|
|
2020
Q4 | – | Sell |
-185,792
| Closed | -$25.2M | – | 385 |
|
|
2020
Q3 | $25.2M | Buy |
185,792
+178,550
| +2,465% | +$24.2M | 1.63% | 4 |
|
|
2020
Q2 | $990K | Buy |
+7,242
| New | +$923K | 0.05% | 248 |
|
|
2020
Q1 | – | Sell |
-2,364
| Closed | -$285K | – | 332 |
|
|
2019
Q4 | $285K | Buy |
+2,364
| New | +$264K | 0.01% | 294 |
|
|
2019
Q2 | – | Sell |
-4,162
| Closed | -$465K | – | 254 |
|
|
2019
Q1 | $465K | Buy |
+4,162
| New | +$456K | 0.07% | 171 |
|
|
2017
Q2 | – | Sell |
-3,318
| Closed | -$324K | – | 137 |
|
|
2017
Q1 | $324K | Sell |
3,318
-1,818
| -35% | -$174K | 0.14% | 119 |
|
|
2016
Q4 | $454K | Sell |
5,136
-28,935
| -85% | -$2.63M | 0.94% | 34 |
|
|
2016
Q3 | $3.29M | Buy |
+34,071
| New | +$3.24M | 1.81% | 13 |
|
|
2016
Q2 | – | Sell |
-12,960
| Closed | -$1.13M | – | 60 |
|
|
2016
Q1 | $1.13M | Buy |
12,960
+9,441
| +268% | +$844K | 1.27% | 25 |
|
|
2015
Q4 | $397K | Sell |
3,519
-12,366
| -78% | -$1.34M | 1.13% | 33 |
|
|
2015
Q3 | $1.61M | Sell |
15,885
-25,233
| -61% | -$3.03M | 2.81% | 8 |
|
|
2015
Q2 | $5.06M | Buy |
41,118
+38,238
| +1,328% | +$4.58M | 3.49% | 5 |
|
|
2015
Q1 | $330K | Buy |
+2,880
| New | +$318K | 0.43% | 61 |
|
|
2014
Q4 | – | Sell |
-5,838
| Closed | -$532K | – | 70 |
|
|
2014
Q3 | $532K | Sell |
5,838
-1,650
| -22% | -$145K | 0.46% | 46 |
|
|
2014
Q2 | $642K | Buy |
+7,488
| New | +$590K | 0.41% | 51 |
|
Other funds holding IBB
CB
Edgestream Partners's IBB Position: Q2 2026 in Review
Edgestream Partners opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 1,181 shares worth $225K. The stake represents 0.01% of the portfolio and ranks #904 among its holdings. This is a return to the name: Edgestream Partners previously reported a position in IBB as recently as Q4 2025.
Edgestream Partners first reported a position in IBB in Q2 2014 and has held it in 28 quarters since. The position peaked at $25.2M in Q3 2020. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.
- Edgestream Partners held 1,181 shares of iShares Biotechnology ETF worth $225K as of Q2 2026.
- iShares Biotechnology ETF was a new Edgestream Partners position in Q2 2026.
- iShares Biotechnology ETF made up 0.01% of Edgestream Partners's portfolio in Q2 2026, its #904 holding.
- Edgestream Partners first reported a position in iShares Biotechnology ETF in Q2 2014 and has held it in 28 quarters since.
- Edgestream Partners's iShares Biotechnology ETF position peaked at $25.2M in Q3 2020.
- 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.
Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.